INTENSIVE PHARMACOKINETIC STUDIES OF ANTIRETROVIRAL DRUG COMBINATIONS HIV

抗逆转录病毒药物组合 HIV 的深入药代动力学研究

• 批准号: 8174501
• 负责人: MARGARET A KELLER
• 金额: $ 0.86万
• 依托单位: LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-12-01 至 2010-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8174501
• 关键词: 18 year old; Adolescent; Anti-Retroviral Agents; Body Surface Area; Child; Computer Retrieval of Information on Scientific Projects Database; Drug Combinations; Drug Kinetics; Funding; Grant; Hour; Institution; Nucleosides; Pharmaceutical Preparations; Protease Inhibitor; Regimen; Research; Research Personnel; Resources; Reverse Transcriptase Inhibitors; Ritonavir; Sampling; Source; Tenofovir; United States National Institutes of Health; dosage; interest; non-nucleoside reverse transcriptase inhibitors

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. P1058 Version 2.0 is an intensive 24-hour pK study of the pharmacokinetics of selected antiretroviral drugs in HIV-infected children > or <18 years of age who are receiving or about to initiate a regimen of antiretrovirals that includes one of the drugs or drug combinations of interest. The objectives are divided into three groups. 1) Assess the steady state by pK sampling of orally administered tenofovir given in combination with nucleoside reverse transcriptase inhibitors (NRTI) and non-nucleoside reverse transcriptase inhibitors (NNRTI) to older children and adolescents. 2) Assess the steady state by pK sampling of orally administered concomitant therapies such as boosted protease inhibitors (PI) such as darunavir/ritonavir used with tenofovir in older children and adolescents. 3) Describe the relationship between a subject?s body surface area (BSA) and tenofovir exposure during treatment with a fixed dosage at steady state with or without concomitant PI treatment.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 P1058 2.0版是一项针对选定抗逆转录病毒药物在>或<18岁的HIV感染儿童中的药代动力学的24小时pK研究，这些儿童正在接受或即将开始一种抗逆转录病毒治疗方案，其中包括一种感兴趣的药物或药物组合。 这些目标分为三组。1)通过PK采样评估年龄较大的儿童和青少年口服替诺福韦与核苷逆转录酶抑制剂（NRTI）和非核苷逆转录酶抑制剂（NNRTI）联合给药的稳态。2)通过pK采样评估口服伴随治疗的稳态，如加强蛋白酶抑制剂（PI），如地瑞那韦/利托那韦与替诺福韦一起用于年龄较大的儿童和青少年。3)描述一个主题之间的关系？的体表面积（BSA）和替诺福韦暴露在治疗过程中的固定剂量在稳态与或不伴随PI治疗。